Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). EyePoint announced financial results for the quarter ended September 30, 2026.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- EyePoint announced financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and accompanying company updates
Item EX-99.1 · Exhibit EX-99.1
- DME becomes EyePoint’s sole late-stage focus after wet AMD Phase 3 failures on primary BCVA non-inferiority endpoints
- COMO and CAPRI fully enrolled with over 550 patients, topline data expected early Q4 2027
- Strategic prioritization includes approximately 53% workforce reduction and approximately $30 million annualized savings
- Cash, equivalents and marketable securities $118 million at September 30, 2026, plus $10 million raised afterward, funding operations into late Q3 2027
- Q3 net loss $95.6 million, or $1.07 per share, with operating expenses $97.6 million versus $63.0 million year over year
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.